Search results for Durvalumab

Durvalumab Biosimilar – Research Grade mAb, ProteoGenix, PX-TA1002-

Durvalumab, Kyinno, KB-1244

Durvalumab, Abbexa, abx831328

Durvalumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD274, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0. 1 and 0. 04 nM, respectively. （适用于人源及非人源化小鼠）

Durvalumab Antibody, Abbexa, abx376602

Durvalumab Antibody is a rabbit polyclonal antibody for the detection of Durvalumab.

Durvalumab ELISA Kit, ProteoGenix, KPTX281

Description of Durvalumab ELISA Kit Introduction Durvalumab, also known as MEDI4736, is a human monoclonal antibody that targets the programmed death-ligand 1 (PD-L1) protein. It is a therapeutic target for various types of cancer, including non-small cell lung cancer, bladder cancer, and head and neck cancer. Durvalumab works by blocking the interaction between PD-L1 and its receptor, programmed cell death protein 1 (PD-1), on immune cells. This prevents the PD-L1 protein from suppressing the immune response, allowing the body’s own immune system to attack and kill cancer cells. The use of Durvalumab as a cancer treatment has shown promising results in clinical trials and has been approved by the US Food and Drug Administration (FDA) for certain types of cancer. Structure of Durvalumab Durvalumab is a fully human IgG1 monoclonal antibody, meaning it is derived from human cells and is of the IgG1 class of immunoglobulins. It is composed of two heavy chains and two light chains, each with a variable region that specifically binds to PD-L1. The constant region of the antibody allows for interactions with immune cells and other proteins in the body. This structure is important for the stability and function of the antibody, allowing it to effectively target PD-L1. Activity of Durvalumab The primary mechanism of action of Durvalumab is the blockade of PD-L1, which is expressed on the surface of cancer cells. PD-L1 binds to PD-1 on immune cells, leading to the suppression of the immune response and allowing cancer cells to evade detection and destruction by the immune system. By binding to PD-L1, Durvalumab prevents this interaction and allows the immune system to recognize and attack cancer cells. Additionally, Durvalumab may also induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which are processes that involve the activation of immune cells to kill cancer cells. Application of Durvalumab ELISA Kit The Durvalumab ELISA Kit is a valuable tool for the detection and quantification of Durvalumab in biological samples. ELISA (enzyme-linked immunosorbent assay) is a commonly used technique in the field of immunoassay, which allows for the specific detection and measurement of a target protein or antibody in a sample. The Durvalumab ELISA Kit utilizes a sandwich ELISA method, where a specific antibody is coated onto a microplate and used to capture Durvalumab from a sample. A second antibody, labeled with an enzyme, is then added and binds to Durvalumab, allowing for the detection and quantification of the antibody. This kit can be used for the measurement of Durvalumab in serum, plasma, and cell culture supernatant, making it a versatile tool for research and clinical applications. Benefits of Durvalumab ELISA Kit The Durvalumab ELISA Kit offers several advantages over other methods of Durvalumab detection. Firstly, it is highly sensitive and specific, allowing for the accurate measurement of Durvalumab even at low concentrations. It is also a quick and easy-to-use method, with results obtained in a matter of hours. The kit is also cost-effective, as it eliminates the need for expensive equipment and specialized training. Additionally, the Durvalumab ELISA Kit can be used for high-throughput screening, making it a valuable tool for large-scale studies. Conclusion The development of Durvalumab as a therapeutic antibody has provided a promising treatment option for various types of cancer. Its specific targeting of PD-L1 allows for the activation of the immune system to fight against cancer cells. The Durvalumab ELISA Kit is a valuable tool for the detection and quantification of this antibody, providing researchers and clinicians with a reliable and

Durvalumab ELISA Kit, Abbexa, abx395170

Durvalumab ELISA Kit is a quantitative ELISA kit for detection of Durvalumab.Durvalumab (dur val" ue mab) is a human recombinant monoclonal IgG1 kappa-isotype antibody to the ligand for programmed cell death receptor-1 (PD-L1) which leads to enhanced T cell responses against cancer cells and is used in cancer immunotherapy. PD-1 is an important checkpoint molecule that modulates and down regulates T cell responses. Inhibition of the PD-L1 prevents its binding to the programmed cell death receptor 1 which is responsible for down regulating T cell responses. Inhibition of this pathway allows for a continued activation and proliferation of T cells. The subsequent enhancement of cytotoxic reactivity may play a beneficial role in cancer immunotherapy by breaking immunological tolerance to cancer cell neo-antigens. In several large multicenter studies, durvalumab therapy resulted in a prolongation of survival in patients with advanced, metastatic or unresectable urothelial carcinoma, and a proportion of patients had a long term remission.

Anti-Durvalumab Polyclonal Antibody, AntibodySystem, PAJ70101

Durvalumab Biosimilar - Research Grade, ichor.bio, ICH5005

Detects human PDL-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Durvalumab.